Aurisco has been deeply involved in the pharmaceutical industry for more than 20 years and commits itself to continuous technological innovation. Today the company is playing a leading role in China in the field of complex synthesis, synthetic biology, photochemistry etc. And has become a long-term partner of the well-known pharmaceutical companies worldwide
Aurisco Pharmaceutical today announced that its manufacturing site in Badu, Tiantai has successfully passed a USFDA cGMP inspection, which lasted for 5 days , from March 17 to March 21,2025. The inspection conclusion is NAI (No Action Indicated).
On May 12, 2025, Luiz Inácio Lula da Silva, President of the Federative Republic of Brazil, met with Peng Zhien, Chairman of Aurisco in Beijing.
East China Normal University and Aurisco Pharmaceutical Co., Ltd. jointly inaugurated AI-Driven Oligonucleotide Drugs Discovery Laboratory. The signing and inauguration ceremony of the AI-Driven Oligonucleotide Drugs Discovery Joint Laboratory was held at East China Normal University's Putuo Campus.
4
Manufacturing Facilities5
R & D Centers260+
Scientists400+
Partnerships1700+
Staff members